Contract Commercialisation Market (CCOs)
CCOs offer a broad range of commercialisation services to their customers, typically focussed on preparing new products for launch and maximising sales post approval.
Read moreMaximising opportunities
We work closely with entrepreneurs and investors at the forefront of the global healthcare revolution. Our in-depth sector knowledge, combined with our technical capability, enables us to help corporates and investors capitalise on the enormous opportunities across the sector as they seek to consolidate and grow their market positions.
The ageing population, technological change, and increased demand for healthcare products and services, all create great opportunities in the health and social care, medical devices, life sciences, bioscience and pharmaceutical markets. Our job is to help our clients maximise those opportunities.
Our latest transactions
-
Clearwater Advisers
Adviser to Laboratorios Ordesa on the acquisition of Laboratorios Sodeinn, S.L.
View more -
Clearwater Advisers
Adviser to shareholding management on the sale of a majority stake in Aegide Domitys to AG2R La Mondiale
-
Clearwater Advisers
Advisor to SRS on its reinvestment in DomusVi alongside ICG and Management
View more -
Clearwater Advisers
Adviser to Palatine Private Equity on its investment in Routes Healthcare
View more -
Clearwater Advisers
Adviser to PRIMA on its majority sale to Lideta
View more -
Clearwater Advisers
Adviser to VIGO Health on its investment from Irish Life Group
View more -
Clearwater Advisers
Adviser to the shareholders of Didactic on the sale of a majority stake of the Group to FCDE
View more -
Clearwater Advisers
Adviser to Unilabs on the sale of 100% of the share capital of Unilabs Italia Srl. to Lifebrain
View more -
Clearwater Advisers
Adviser to Naxicap on the acquisition of a majority stake in Laguarrigue from Ardian
View more -
Clearwater Advisers
Adviser to the shareholders of CVC Capital Partners, 3i and KKR, and Careit on the acquisition of Essling Capital and its financing
View more -
Clearwater Advisers
Adviser to Sagitta Pharma's shareholder in Isatis Capital's majority LBO
View more -
Clearwater Advisers
Adviser to the shareholders of Nathura on the sale to Giuliani
View more
Luc Bertholat, Partner, Naxicap PartnersClearwater has been very professional in leading the process involving candidates from all over the world.
Our Healthcare Team
The team were quickly able to identify the right partner for us and used their excellent relationship with the buyer to help negotiate a transaction that met our objectives.Dan Smart, CEO, Proclinical
With in-depth knowledge and technical capability, our healthcare team has a great track record of delivering tailored solutions.
See our teamOver 65
deals advised upon
in the last 5 years
€9.4bn
deal value
over the last 5 years
Over 40%
deals involving PE
in the last 5 years
Insights
-
-
Contract Development and Manufacturing Market (CDMOs)
As innovator pipelines have deepened and the complexities of developing and manufacturing more recent generations of pharma (including biologics) have increased, the need to simplify manufacturing operations and reduce operating expenditure has led to the emergence of the CDMO industry.
Read more -
Contract Research Organisations (CROs)
CROs are constantly expanding their addressable markets by broadening their service offerings, capturing an increasing share of pharma R&D expenditure. Investment in technology and big data will continue to play an important role in the expansion of the CRO sub-sector.
Read more
